“`html
Study Summary: PD-1 Inhibitor Combined with SOX for Gastric Cancer
Gastric cancer (GC) is a common and deadly tumor, often diagnosed at an advanced stage. Postoperative adjuvant chemotherapy for advanced GC has limited effectiveness, leading to high rates of distant metastasis and local recurrence.
Objective
To assess the safety and effectiveness of combining a PD-1 inhibitor with oxaliplatin and S-1 (SOX) in treating Borrmann large type III and IV GCs.
Methods
- Retrospective analysis of 89 patients with Borrmann large type III and IV GCs who received neoadjuvant therapy (NAT) from January 2020 to December 2021.
- Patients were divided into the SOX group (61 patients) and the PD-1 + SOX (P-SOX) group (28 patients) based on their neoadjuvant treatment regimens.
Results
- The P-SOX group showed a significantly higher pathological response compared to the SOX group (42.86% vs 18.03%).
- Incidence of ypN0 (no regional lymph node metastasis) was higher in the P-SOX group compared to the SOX group (39.29% vs 19.67%).
- Use of PD-1 inhibitors was an independent factor affecting tumor regression grade, without increasing postoperative complications or adverse effects of NAT.
Conclusion
Combining a PD-1 inhibitor with SOX significantly improved tumor regression rates during NAT for patients with Borrmann large type III and IV GCs.
“`
